ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Ankylosing spondylitis (AS)"

  • Abstract Number: 0525 • ACR Convergence 2023

    Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies

    Marina Nighat Magrey1, Marleen van de Sande2, Maxime Breban3, Filip Van den Bosch4, Carmen Fleurinck5, Ute Massow6, Natasha De Peyrecave7, Thomas Vaux8, Xenofon Baraliakos9 and Helena Marzo-Ortega10, 1Case Western Reserve University, University Hospitals, Cleveland, OH, 2Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, 3CHU Ambroise-Paré, Boulogne-Billancourt, Paris, France, 4Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, 5UCB Pharma, Oosterzele, Belgium, 6UCB Pharma, Monheim am Rhein, Germany, 7UCB Pharma, Brussels, Belgium, 8UCB Pharma, Slough, United Kingdom, 9Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 10NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom

    Background/Purpose: In patients (pts) with axial spondyloarthritis (axSpA), tumor necrosis factor inhibitors (TNFi) are the usual first line biologic treatment, yet many pts may experience…
  • Abstract Number: 1349 • ACR Convergence 2023

    Paternal Effects of Anti-TNFs in Inflammatory Arthritis

    Zeynep Toker Dincer, Bahaddin Ates, Ayten Dag, Ilayda Turkoglu, Ali Yagiz Ayla and Serdal Ugurlu, Istanbul University-Cerrahpasa, Istanbul, Turkey

    Background/Purpose: Inflammatory arthritis is a group of rheumatic diseases characterized by the inflammation of joints with systemic manifestations: psoriatic arthritis (PsA), rheumatoid arthritis (RA), and…
  • Abstract Number: 1405 • ACR Convergence 2023

    Diagnostic Delay of Axial Spondyloarthritis in African American Patients

    John Byun1, Hans Vitzthum von Eckstaedt1, Kichul Ko2 and Reem Jan1, 1University of Chicago, Chicago, IL, 2The University of Chicago, Chicago, IL

    Background/Purpose: The identification of axial spondyloarthritis (axSpA) remains challenging. The initial presentation is not always immediately apparent as an inflammatory disease, potentially leading to years…
  • Abstract Number: 1892 • ACR Convergence 2023

    Sacroiliac Bone Marrow Oedema on Postpartum MRI Does Not Result in Significant SpA-like Structural Lesions: Results of a 5-year Follow-up Study

    De Meester Liesbet1, Gaelle Varkas2, Manouk de Hooge3, Ann-Sophie De Craemer4, Nele Herregods5, Lennart Jans5, Philippe Carron6, Dirk Elewaut7 and Filip Van den Bosch8, 1Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, 2Dept. of Rheumatology, Ghent University Hospital, Ghent, Belgium, 3Ghent University Hospital, Hesperange, Luxembourg, 4Ghent University Hospital, Gent, Belgium, 5Department of Radiology, Ghent University Hospital, Ghent, Belgium, 6UZ Gent, Gent, Belgium, 7Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, 8Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium

    Background/Purpose: Sacroiliac bone marrow oedema (BMO) on MRI, immediately after childbirth, has been observed in a large proportion of postpartum women and appears to be…
  • Abstract Number: 0526 • ACR Convergence 2023

    Bimekizumab Improved Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 52-Week Results from Two Phase 3 Studies

    Maureen Dubreuil1, Karl Gaffney2, Jonathan Kay3, Victoria Navarro-Compán4, Christine de la Loge5, Alicia Ellis6, Carmen Fleurinck7, Ute Massow8, Vanessa Taieb9 and Atul Deodhar10, 1Department of Rheumatology, Boston University School of Medicine, Milton, MA, 2Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom, 3Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA, 4Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, 5UCB Pharma, Brussels, Belgium, 6UCB Pharma, Raleigh, NC, 7UCB Pharma, Oosterzele, Belgium, 8UCB Pharma, Monheim am Rhein, Germany, 9UCB Pharma, Colombes, France, 10Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR

    Background/Purpose: Axial spondyloarthritis (axSpA) severely impairs physical function and health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in…
  • Abstract Number: 1383 • ACR Convergence 2023

    Long-term Association Between Physical Activity and Global Functioning in Patients with axSpA: Results of a 2 Year Prospective Study

    Kwi Young Kang1 and Hyoun-Ah Kim2, 1Catholic University of Korea, Seoul, South Korea, 2Ajou University School of Medicine, Suwon, South Korea

    Background/Purpose: To assess the longitudinal association between physical activity and global functioning in patients with axial spondyloarthritis (axSpA) and to identify the subtype of physical…
  • Abstract Number: 1406 • ACR Convergence 2023

    Temporal Trends in Cardiovascular Events in Axial Spondyloarthritis Patients with Medicare Insurance versus Commercial Insurance: An Analysis Using Claims Data

    Rouhin Sen1, Justin Leach1, Maria I. ("Maio") Danila2, Fenglong Xie1, Jasvinder Singh1, Liron Caplan3, Iris Navarro-Millán4 and Jeffrey Curtis1, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, 3Rocky Mountain Regional VAMC, Aurora, CO, 4Weill Cornell Medicine, Hospital for Special Surgery, New York, NY

    Background/Purpose: AS is an inflammatory disorder of the axial skeleton and can cause complications including disabling joint damage. Nearly 20% of people with AS are…
  • Abstract Number: 2164 • ACR Convergence 2023

    Real-world Persistence of Initial Targeted Therapy Strategy in Monotherapy versus Combination Therapy in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

    Carlos Sánchez-Piedra1, Lorena Expósito2, PALOMA VELA3, Manuel José Moreno Ramos4, Cristina Campos5, Cristina Bohorquez6, Jerusalem Calvo7, Zulema Plaza8, Marta Domínguez9 and Jose Federico Diaz-Gonzalez10, 1Health Technology Assessment Agency (AETS), Instituto de Salud Carlos III, Madrid, Spain, 2Rheumatology Unit, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Spain, 3Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, 4Rheumatology Department Hospital Virgen de la Arrixaca, El Palmar Murcia, Spain, 5Rheumatology Unit, Hospital General Universitario de Valencia, Valencia, Spain, 6Rheumatology Unit, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain, 7Reina Sofia University Hospital, Córdoba, Spain, 8Universidad Autónoma de Madrid, Madrid, Spain, 9Sociedad Española de Reumatología, Madrid, Spain, 10Hospital Universitario de Canarias, La Laguna, Spain

    Background/Purpose: Clinical practice guidelines, based on information from clinical trials, provide different recommendations for the use of combination therapies for the treatment of rheumatoid arthritis…
  • Abstract Number: 0528 • ACR Convergence 2023

    Risk of Cardiovascular Disease Associated with Long-term Use of NSAIDs in Ankylosing Spondylitis

    Seong-Kyu kim1, Ji-Won kim1, Jun Sik Yoon2, bo young Kim3, Hwajeong Lee1, Sung-Hoon Park1 and Jung-Yoon Choe1, 1Daegu Catholic University School of Medicine, Daegu, South Korea, 2Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea, 3Daegu Catholic University Medical Center, Daegu, South Korea

    Background/Purpose: Ankylosing spondylitis (AS) is associated with increased cardiovascular disease, but there are limited data as to whether prolonged treatment with non-steroidal anti-inflammatory drugs (NSAIDs)…
  • Abstract Number: 1384 • ACR Convergence 2023

    Functional Status by Sex and Socioeconomic Status in Axial Spondyloarthritis

    Rachael Stovall1, Jing Li1, zara izadi1, Lianne Gensler2, Gabriela Schmajuk3 and Jinoos Yazdany4, 1University of California San Francisco, San Francisco, CA, 2University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, 3UCSF / SFVA, San Francisco, CA, 4University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA

    Background/Purpose: Women with axial spondyloarthritis (axSpA) tend to have worse patient reported outcomes compared to men. Non-U.S. studies have evaluated functional status (FS) by sex…
  • Abstract Number: 1407 • ACR Convergence 2023

    Defining Thresholds of Presenteeism Measures for Unacceptable Work Participation in axSpA

    Dafne Capelusnik1, Sofia Ramiro2, Elena Nikiphorou3, Walter P. Maksymowych4, Marina Nighat Magrey5, Helena Marzo-Ortega6 and Annelies Boonen7, 1Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3King's College London, London, United Kingdom, 4University of Alberta, Edmonton, AB, Canada, 5Case Western Reserve University, University Hospitals, Cleveland, OH, 6NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 7Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands

    Background/Purpose: Presenteeism is associated with lower work satisfaction and future sick leave in axial spondyloarthritis (axSpA). It is generally assessed as a continuous variable; however,…
  • Abstract Number: 2213 • ACR Convergence 2023

    Identification of a Diagnostic Model for Axial Spondyloarthritis in Daily Clinical Practice Using a Random Forest Machine Learning Approach

    Imke Redeker1, Styliani Tsiami2, Jan Eicker3, Uta Kiltz4, David Kiefer2, Ioana Andreica5, Philipp Sewerin2 and Xenofon Baraliakos6, 1Ruhr Universität Bochum, Bochum, Germany, 2Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany, 3Rheumazentrum Ruhrgebiet Herne and Ruhr-University Bochum, Herne, Germany, 4Rheumazentrum Ruhrgebiet, Herne, Germany, 5Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 6Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany

    Background/Purpose: In axial spondyloarthritis (axSpA), early diagnosis plays a key role in preventing disease progression. However, a validated diagnostic algorithm does not exist, while classification…
  • Abstract Number: 0090 • ACR Convergence 2023

    Reduced Frequency of RORγt+ Regulatory T Cells Is Associated with Secukinumab Response in Axial Spondyloarthritis

    Addison Pacheco1, Michael Tang1, Sinead Maguire2, Melissa Lim1, Fataneh Tavasolian3, Zoya Qaiyum4 and Robert Inman1, 1University Health Network, Toronto, ON, Canada, 2Toronto Western Hospital, Toronto, ON, Canada, 3Krembil Research Institute, University Health Network, Toronto, ON, Canada, 4Krembil Research Institute, Toronto, ON, Canada

    Background/Purpose: Axial spondyloarthritis (AxSpA) is an inflammatory disease that predominantly affects the spine and the sacroiliac joints. Dysregulation of Type 3 immunity has been implicated…
  • Abstract Number: 0531 • ACR Convergence 2023

    Effects of Anti-tumor Necrosis Factor Treatment on Lipid Profiles in Patients with Ankylosing Spondylitis

    Inbeom Kwon1, bora nam2, Nayeon Choi3, Ji-Hui Shin2, Seunghun lee4 and Tae-Hwan Kim2, 1Department of Medicine, Hanyang University College of Medicine, Seoul, South Korea, 2Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 3Biostatistical Consulting and Research Lab, Medical Research Collaborating Center, Hanyang University, Seoul, South Korea, 4Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea

    Background/Purpose: To investigate the effects of anti-tumor necrosis factor (anti-TNF) treatment on lipid profiles and identify risk factors for elevated total cholesterol (TC) after the…
  • Abstract Number: 1385 • ACR Convergence 2023

    Where Are We with Implementing Axial Spondyloarthritis Treatment Recommendations and Disease Activity Monitoring in Clinical Practice – Results of an Online Survey Amongst Rheumatology Care Providers

    Joerg Ermann1, Stephanie Sinnappan2 and Alexandra Forte3, 1Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Memorial Sloan Kettering Cancer Center, New York, NY

    Background/Purpose: Several sets of treatment recommendations for axial spondyloarthritis and ankylosing spondylitis (axSpA/AS) have been published. Clinical practice guidelines are not followed consistently by health…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 62
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology